Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eylea dosing schedule comparison with ERG assessment in wet AMD
2014-003229-17Phase 4Completed
- Sponsor
- Lund University
- Start
- Aug 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aflibercept in exudative macular degeneration (2 arms), sponsored by Lund University. Primary endpoint: Efficacy. Started Aug 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2014-003229-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003229-17.